Skip to main content

Table 1 Parameter estimates and their probability distributions used to populate the model

From: The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD

Parameter

Assumed input value at GOLD stages

Assumed probability distribution at GOLD stages

II

III

II

III

Annual COPD mortality [20]

0.00393

0.006762

--

--

Utility and disutilities [19]

  

Baseline

0.72

0.67

B(160, 62)

B(59, 29)

Minor exacerbation

0.658

0.475

B(164, 85)

B(47, 52)

Major exacerbation

0.447

0.408

B(22, 27)

B(39, 57)

Exacerbations rates and probabilities [19]

   

Frequency

1.22

1.47

Γ(14884, 12200)

Γ(21609, 14700)

Minor (%)

0.93

0.90

Γ(8649, 9300)

Γ(8100, 9000)

Major (%)

0.07

0.10

Γ(12.25, 175)

Γ(25, 250)

Minor exacerbation

80$

134$

Γ(320, 4)

Γ(536, 4)

Major exacerbation

3250$

5417$

Γ(13000, 4)

Γ(21668, 4)

Indirect maintenance cost [20]

215$

524$

Γ(860, 4)

Γ(2096, 4)

Direct exacerbations costs ($) [19]

    

Minor exacerbations

161$

Γ(644, 4)

Major exacerbations

6501$

Γ(26004, 4)

General practitioner visit

70$

Γ(280, 4)

Specialist visit

90$

Γ(360, 4)

Direct medication costs ($) [ [22]

   

Inhaled corticosteroids (ICS)

450$

--

Long-acting beta-agonists (LABA)

500$

--

ICS + LABA

1000$

--

Long-acting muscarinic agents

750$

--